The New Breakthrough Appetite Suppressant - PowerPoint PPT Presentation

1 / 32
About This Presentation
Title:

The New Breakthrough Appetite Suppressant

Description:

In July 2003, NBJ cited the Weight Loss segment as one of the largest condition ... Overnight fasting. Simple breakfast 3 g of supplement in capsules: PinnoThin or ... – PowerPoint PPT presentation

Number of Views:206
Avg rating:3.0/5.0
Slides: 33
Provided by: sandraei
Category:

less

Transcript and Presenter's Notes

Title: The New Breakthrough Appetite Suppressant


1
  • The New Breakthrough Appetite Suppressant

2
Presentation
  • Obesity
  • Mechanism - Appetite Suppression
  • Trial PinnoThin - Results
  • Recommendations
  • Claims

3
Weight Management Market
  • In July 2003, NBJ cited the Weight Loss segment
    as one of the largest condition markets in the
    U.S. with expected market growth at 4.7
  • Appetite suppressants account for 13 of the US
    slimming aids market

4
Weight Management Market
5
European National Obesity Rates
WHO-International Obesity Task Force, 2005
6
Prevalence of Obesity across the World
WHO-International Obesity Task Force, 2005
7
Obesity Health Risks
Cancer
Hyper- tension
Gallbladder disease
Obesity
Type 2 diabetes
Kidney Failure
Athero- sclerosis
Stroke
Heart Failure
  • Estimates of obesity related costs up to 8 of
    overall health budget

WHO-International Obesity Task Force 2004
8
Weight Management
Appetite Suppression
9
Where does PinnoThin come from?
  • Over 144 pine trees exist
  • PinnoThin comes from the Korean pine tree
    (Pinus koraiensis)
  • Pinus koraiensis grows in Korea, Japan,
    Siberia and Manchouria (North of
    China)
  • PinnoThin contains pinolenic acid
  • Pinolenic acid LCPUFA Omega-6 C183 - 5,9,12
    (all cis)

9
12
CH3
COOH
5
10
Importance of Pine Nut Oil Origin
Korean Pine
Italian Stone Pine
11
Regulation of Digestion and Absorption of Food
  • Regulated by
  • Hormonal system
  • Nervous system
  • Reasons for meal termination
  • Fullness or absence of hunger
  • Decline in pleasantness or reward value of the
    food being eaten

Graaf, de et al., 2004
12
Meal Termination
  • Depends on
  • Short-term signals such as stomach distension and
    on gut hormones like cholecystokinin (CCK) and
    glucagon-like peptide 1 (GLP1)
  • Sensitivity to these short-term signals is
    affected by signals that work in the long term
    like leptin and grhelin

Graaf, de et al., 2004
13
Appetite controllers
CCK cholecystokinin GLP1 glucagon-like
peptide 1
14
Cholecystokinin (CCK)
  • Small intestinal hormone (first part)
  • Reduces appetite and food intake
  • Determines meal size or meal termination
    (satiation)
  • Released upon fat or protein intake
  • Slows down gastric emptying

15
Cholecystokinin (CCK)
  • CCK suppresses appetite, and higher amounts of
    CCK produce larger appetite-suppressing effects
  • Fatty acids gt C10 are effective in releasing CCK
  • Long chain fatty acids are more effective than
    medium chain fatty acids
  • Poly unsaturated fatty acids are more effective
    than mono-unsaturated fatty acids

Burton-Freeman et al., 2004 Burton-Freeman et
al., Degen et al., 2001 Gutzwiller et al.,
2004 McLaughlin et al., 1999 Matzinger et al.,
2000 Lawton et al., 2000
16
Glucagon-like peptide 1 (GLP1)
  • Small intestinal hormone (last part)
  • Reduces appetite and food intake
  • Determines meal size or meal termination
    (satiation)
  • Released upon fat and carbohydrates intake
  • Delays gastric emptying

17
Gut responds to Fatty Acids by producing CCK
18
In Vitro Activity of PinnoThin
Low dose 100 uM
High dose 300 uM
19
Lipid Nutrition Human Trial at TNO, 2005
  • Randomized, double blinded, placebo-controlled,
    cross-over trial
  • Women n18 (all women tested placebo and
    PinnoThin)
  • BMI 25 30 (mean BMI 27.4 1.6)
  • Age 55 4
  • Weight 76.7 6.7
  • Overnight fasting
  • Simple breakfast 3 g of supplement in capsules
  • PinnoThin or
  • Placebo (olive oil)
  • Subjects were monitored during 4 hours
  • Satiety score (VAS) (subjective)
  • CCK and GLP1 levels (objective)

20
CCK is increased by PinnoThin
Cholecystokinin (CCK)

PinnoThin Placebo



significant difference
21
Total CCK in 4 hours after Supplementation
CCK level after PinnoThin 60 gt placebo (P lt
0.0001)
Area Under the Curve
22
GLP1 is increased by PinnoThin
Glucagon like peptide 1 (GLP1)
PinnoThin Placebo


significant difference
23
Total GLP1 in 4 hours after Supplementation
GLP1 level after PinnoThin 25 gt placebo
(Plt0.05)
AUC Area Under the Curve
24
Summary of the results
  • PinnoThin significantly increases CCK and GLP1
    in blood within 30-60 min
  • Total CCK and GLP1 levels remain higher than
    placebo for at least 3 hours after PinnoThin
    intake
  • Desire to eat and the prospective intake scores
    are significantly lower after 30 min
  • PinnoThin reduces the desire to eat with 29 at
    30 minutes relative to placebo
  • PinnoThin reduces the prospective food intake
    with 36 at 30 minutes relative to placebo
  • Conclusion
  • PinnoThin may thus affect meal size

25
Recommendations
  • To reduce meal size
  • 3 g PinnoThin 30 60 minutes before a meal
  • Intake ideally before meal with highest energy
    content
  • To reduce snacking
  • 3 g PinnoThin in between meals

Maximal daily dose is 6 g per day
26
Safety of 6 g / day
  • History of use in humans
  • Animal studies
  • Ames-test using Pine Nut Oil
  • Clearance from Covance
  • (The Development Services Company)

27

Applications
  • PinnoThin is available in
  • Triglyceride (TG) form
  • Applications
  • As supplement in TG form
  • In food as TG form
  • Beverages, bars, dressings etc

28
Regulatory Patents
  • Regulatory
  • EU not a Novel Ingredient because of history of
    use
  • US PinnoThin TG is GRAS
  • PinnoThin FFA - NDI submission will be filed,
  • expectations for allowance end 2005
  • Patents
  • PinnoThin is protected for its specific uses in
    food, food supplements and pharmaceuticals
  • Patent PinnoThin as health component (EP 1088552
    US6479070 JP 300280/00 KR 10200057291)
  • Patent on composition (EP 1088552)

29
LNs Patented Claims include
  • PinnoThin promotes the feeling of satiety
  • PinnoThin suppresses the desire to eat
  • PinnoThin reduces the prospective food intake
  • PinnoThin significantly increases the release of
    CCK
  • PinnoThin significantly increases the release of
    GLP1

30
Examples Consumer Claims
  • PinnoThin is an effective appetite suppressant
  • PinnoThin can help to reduce your caloric intake
  • PinnoThin can help to reduce snacking
  • PinnoThin supports to reduce the food intake
  • PinnoThin can control your weight
  • PinnoThin gives you control on your appetite
  • Structure-function claim FDA
  • These claims are not approved by the FDA and the
    use of these claims depend on the regulations in
  • your country

31
Why PinnoThin?
  • PinnoThin is a scientifically proven appetite
    suppressant
  • PinnoThin is derived from a natural (vegetable)
    source
  • PinnoThin contains the effective components
  • PinnoThin is easy to use
  • PinnoThin can be taken every day

32
  • The New Breakthrough
  • Appetite Suppressant
  • www.lipidnutrition.com
Write a Comment
User Comments (0)
About PowerShow.com